China's Drug Regulator Accepts Huadong Medicine Unit's Marketing Application for Carverilone Tromethamine Tablets

Huadong Medicine (000963.SZ) Subsidiary's Marketing Application for Cavilaglutide Tromethamine Tablets Accepted

Huadong Medicine's Self-Developed Oral GLP-1 Drug Cavililong Receives China Marketing Application Acceptance

Huadong Medicine Logs Lower Q3 Attributable Profit, Revenue

Huadong Medicine Announces Resolutions from Eighth Meeting of Eleventh Board of Directors

Huadong Medicine Q3 Net Profit Down 2.4% Y/Y

Huadong Medicine's Unit Gets Nod for DR30206's Clinical Trial

Huadong Medicine's Unit Gets Nod to Trial Head, Neck Cancer Treatment

Huadong Medicine's Shangkelin Spray Wins Recommendations in Two Authoritative Guidelines, Further Validating Evidence-Based Value of Miao Ethnic External Medicine

Huadong Medicine's HDM1002 Tablet Achieves Topline Results: What Is Its Future Commercial Value?

Huadong Medicine's Weight Management Drug Shows 'Positive' Results in Third Phase Trial

Huadong Medicine's Innovative Oral Small Molecule GLP-1 Agonist HDM1002 Achieves Positive Phase III Weight Loss Results

Chinese Drug Regulator Accepts Huadong Medicine's Registration Application for Primelase Semiconductor Laser Therapy System

Heidelberg Pharma, Huadong Medicine Expand ADC Collaboration to Develop New Drug Candidates

China NMPA Clears Heidelberg Pharma’s HDP-101 Combo Trial in Multiple Myeloma

Huadong Medicine's H1 Profit Rises 3%, Revenue Climbs 2%

Huadong Medicine's Lymphoma Drug Gets US FDA's Fast Track Designation

Huadong Medicine H1 Net Profit up 2.53% Y/Y

Huadong Medicine Secures China Regulatory Nod For Undereye Filler

Press Release: CARsgen Therapeutics Announces 2026 Interim Results